VNDA

Vanda Pharmaceuticals Inc. (VNDA) | Rumor.io

Vanda Pharmaceuticals

VNDA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,513

Bullish sentiment (50-day avg)82%

Price to earnings ratio126

Market capitalization312.6M

Earnings per share-4.64

Dividend yield (TTM)—

Revenue (annual)216.1M

Net income (annual)-220.5M

Social

What share of all stock conversation is about VNDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% +0	0% +0	0% +0

Sep 30

Vanda Pharmaceuticals' Hetlioz treatment showed positive Phase 3 results for delayed sleep-wake phase disorder, with patients experiencing a 37.1-minute earlier sleep onset compared to placebo.
The company plans to discuss the data with the FDA and submit a supplemental new drug application seeking approval for the additional indication, which would make Hetlioz the first FDA-approved treatment for the condition.
The Phase 3 study's results support Hetlioz's potential as a treatment for patients with delayed sleep-wake phase disorder, with a responder rate of 60% experiencing a 30-minute or greater advancement in sleep onset compared to 15% on placebo.

Generated by AI

Sentiment

Of the messages about VNDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	52.5% -9.04	68.53% -31.47	78.1% -16.9	90.88% +7.91
Bearish	47.5% +9.04	31.47% +31.47	21.9% +16.9	9.12% -7.91

Bullish· May 6

VNDA has a strong pipeline with 5 approved drugs, a small float under 60M, and potential regulatory updates.
VNDA's commercial launch and Nereus guidance are exciting, with the company well-positioned to execute on its plans and drive sales.
VNDA has a favorable cash position, with the funds to launch its products, unlike many other biotech companies that have to borrow money to launch theirs.

Bearish· May 6

The market capitalization of VNDA is 450M, and the projected revenue for next year is 260-290M, making the current price of 7 per share potentially overvalued.
VNDA's cash burn is increasing, with a 60% rise in cash burn and a 10% increase in revenue guidance, indicating potential execution issues.
VNDA may be planning to raise funds through a merger and acquisition (MA) opportunity, which could lead to a stock offering and further dilution of shares.

Generated by AI

Topics

Of the messages about VNDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	98.51%	94.37%	46.7%
Technical Analysis	0%	0%	4.23%	17.03%
Analysts	0%	1.49%	1.41%	18.26%
Earnings	0%	0%	0%	1.66%
Controversies	0%	0%	0%	1.69%
Macro	0%	0%	0%	14.66%

Earnings· Aug 1

Vanda Pharmaceuticals ($VNDA) reported FQ2 earnings of 14c EPS and $47.35M in revenue.
$VNDA beat the Estimize EPS Consensus by 5c and the Estimize Revenue Consensus by $0.11M.
The company's Q2 earnings call was held on a specific date, with live and replay options available.

Announcements· Feb 24

Vanda Pharmaceuticals (VNDA) received unsolicited acquisition offers from Future Pak, LLC and Cycle Group Holdings Ltd. in 2024, but the company's Board rejected both offers, stating they significantly undervalued the company.
VNDA secured two FDA approvals in under two months, including BYSANTI (milsaperidone) for schizophrenia and bipolar I disorder in adults, and NEREUS (tradipitant) for prevention of motion-induced vomiting.
VNDA's stock price has increased by 41.49% to $815.00 following the FDA approval of BYSANTI, a new atypical antipsychotic for bipolar disorder and schizophrenia, which has strengthened the company's product portfolio and opened a new market.

Controversies· Jan 8

$VNDA receives FDA decision letter that HETLIOZ sNDA for Jet Lag Disorder cannot be approved in its current form.
FDA rejects Vanda's Hetlioz for jet lag disorder, citing clinical trial design concerns despite positive efficacy data, leading to a 12% drop in $VNDA stock.
Vanda stands firm, disagreeing with FDA's conclusion, after receiving the decision letter for HETLIOZ's supplemental new drug application for jet lag disorder.

Technical Analysis· Feb 23

VNDA has broken its high, indicating a potential pullback to a new high-low over the volume-weighted average price (VWAP), with a possible price increase to $10-$12.
VNDA is in a consolidation phase around $8.20, with a strong possibility of a breakout to $14-$15 if it continues to hold above $8.56.
VNDA's trend is turning up, with the price holding tight near highs, indicating a potential expansion in the near future.

Generated by AI

Community

Of the messages about VNDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	78.1%	88.26%	54.46%	36.35%
Newcomers	21.9%	11.74%	45.54%	63.65%

Regulars· Sep 29

$VNDA's Phase III results show a 37.1-minute shift in sleep onset time in delayed sleep-wake phase disorder patients compared to placebo, meeting the study's primary endpoint.
The company's pipeline is being compared to that of Egetis Therapeutics, which has a market capitalization of $4 billion despite having only one approved drug and no other products in its pipeline.
Vanda Pharmaceuticals has multiple catalysts ahead, including three Phase 3 readouts and an FDA decision, with the recently approved drug BYSANTI expected to be launched in the second half of 2026.

Newcomers· Feb 24

Newcomers are focused on the FDA approval of BYSANTI, a new antipsychotic, as a key catalyst for VNDA's stock performance.
The stock has broken through a key resistance level at $667.30, with a massive volume of 48.05M, and is now targeting a high at $1201.69.
VNDA's strong momentum has pushed the stock up by 41.49%, with some analysts revising their revenue thesis to $73M-$96M.

Generated by AI

News

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

27d agoYahoo Finance

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

1mo agoMorningstar

Also Discussed

Investors talking about VNDA also mention

#	Name	Attention
1	Corcept Therapeutics Inc.CORT	0%new
2	Grace Therapeutics, Inc.GRCE	0%new
3	Travere Therapeutics Inc.TVTX	0%0
4	Outlook Therapeutics Inc.OTLK	0.01%-0.01
5	MannKind CorporationMNKD	0.02%+0.01
6	Agenus Inc.AGEN	0.01%-0.01
7	Esh Acquisition Corp.ESHA	0%0
8	Alchemy Investments Acquisition Corp.ALCY	0%0
9	Nortech Systems IncorporatedNSYS	0%0
10	Zentalis Pharmaceuticals, Inc.ZNTL	0%new

Vanda Pharmaceuticals Inc.

Healthcare
Biotechnology

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its current portfolio centers on treatments for sleep-wake disorders, schizophrenia, and other central nervous system conditions, supported by a selective pipeline that includes additional clinical and preclinical programs. The company’s marketed products include HETLIOZ and Fanapt, while PONVORY adds a presence in immune-related therapeutics. Vanda also works on specialty medicines for rare diseases and other targeted indications, using genetics and genomics to guide drug discovery and clinical development. With a concentrated product mix and a research-driven model, Vanda Pharmaceuticals Inc. plays a specialized role in the biopharmaceutical market by addressing niche patient populations where treatment options may be limited.

Website

Location

2200 Pennsylvania Avenue NW

Washington, DC, 20037

United States

Social

What share of all stock conversation is about VNDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% +0	0% +0	0% +0

Sep 30

Vanda Pharmaceuticals' Hetlioz treatment showed positive Phase 3 results for delayed sleep-wake phase disorder, with patients experiencing a 37.1-minute earlier sleep onset compared to placebo.
The company plans to discuss the data with the FDA and submit a supplemental new drug application seeking approval for the additional indication, which would make Hetlioz the first FDA-approved treatment for the condition.
The Phase 3 study's results support Hetlioz's potential as a treatment for patients with delayed sleep-wake phase disorder, with a responder rate of 60% experiencing a 30-minute or greater advancement in sleep onset compared to 15% on placebo.

Generated by AI

Sentiment

Of the messages about VNDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	52.5% -9.04	68.53% -31.47	78.1% -16.9	90.88% +7.91
Bearish	47.5% +9.04	31.47% +31.47	21.9% +16.9	9.12% -7.91

Bullish· May 6

VNDA has a strong pipeline with 5 approved drugs, a small float under 60M, and potential regulatory updates.
VNDA's commercial launch and Nereus guidance are exciting, with the company well-positioned to execute on its plans and drive sales.
VNDA has a favorable cash position, with the funds to launch its products, unlike many other biotech companies that have to borrow money to launch theirs.

Bearish· May 6

The market capitalization of VNDA is 450M, and the projected revenue for next year is 260-290M, making the current price of 7 per share potentially overvalued.
VNDA's cash burn is increasing, with a 60% rise in cash burn and a 10% increase in revenue guidance, indicating potential execution issues.
VNDA may be planning to raise funds through a merger and acquisition (MA) opportunity, which could lead to a stock offering and further dilution of shares.

Generated by AI

Topics

Of the messages about VNDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	98.51%	94.37%	46.7%
Technical Analysis	0%	0%	4.23%	17.03%
Analysts	0%	1.49%	1.41%	18.26%
Earnings	0%	0%	0%	1.66%
Controversies	0%	0%	0%	1.69%
Macro	0%	0%	0%	14.66%

Earnings· Aug 1

Vanda Pharmaceuticals ($VNDA) reported FQ2 earnings of 14c EPS and $47.35M in revenue.
$VNDA beat the Estimize EPS Consensus by 5c and the Estimize Revenue Consensus by $0.11M.
The company's Q2 earnings call was held on a specific date, with live and replay options available.

Announcements· Feb 24

Vanda Pharmaceuticals (VNDA) received unsolicited acquisition offers from Future Pak, LLC and Cycle Group Holdings Ltd. in 2024, but the company's Board rejected both offers, stating they significantly undervalued the company.
VNDA secured two FDA approvals in under two months, including BYSANTI (milsaperidone) for schizophrenia and bipolar I disorder in adults, and NEREUS (tradipitant) for prevention of motion-induced vomiting.
VNDA's stock price has increased by 41.49% to $815.00 following the FDA approval of BYSANTI, a new atypical antipsychotic for bipolar disorder and schizophrenia, which has strengthened the company's product portfolio and opened a new market.

Controversies· Jan 8

$VNDA receives FDA decision letter that HETLIOZ sNDA for Jet Lag Disorder cannot be approved in its current form.
FDA rejects Vanda's Hetlioz for jet lag disorder, citing clinical trial design concerns despite positive efficacy data, leading to a 12% drop in $VNDA stock.
Vanda stands firm, disagreeing with FDA's conclusion, after receiving the decision letter for HETLIOZ's supplemental new drug application for jet lag disorder.

Technical Analysis· Feb 23

VNDA has broken its high, indicating a potential pullback to a new high-low over the volume-weighted average price (VWAP), with a possible price increase to $10-$12.
VNDA is in a consolidation phase around $8.20, with a strong possibility of a breakout to $14-$15 if it continues to hold above $8.56.
VNDA's trend is turning up, with the price holding tight near highs, indicating a potential expansion in the near future.

Generated by AI

Community

Of the messages about VNDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	78.1%	88.26%	54.46%	36.35%
Newcomers	21.9%	11.74%	45.54%	63.65%

Regulars· Sep 29

$VNDA's Phase III results show a 37.1-minute shift in sleep onset time in delayed sleep-wake phase disorder patients compared to placebo, meeting the study's primary endpoint.
The company's pipeline is being compared to that of Egetis Therapeutics, which has a market capitalization of $4 billion despite having only one approved drug and no other products in its pipeline.
Vanda Pharmaceuticals has multiple catalysts ahead, including three Phase 3 readouts and an FDA decision, with the recently approved drug BYSANTI expected to be launched in the second half of 2026.

Newcomers· Feb 24

Newcomers are focused on the FDA approval of BYSANTI, a new antipsychotic, as a key catalyst for VNDA's stock performance.
The stock has broken through a key resistance level at $667.30, with a massive volume of 48.05M, and is now targeting a high at $1201.69.
VNDA's strong momentum has pushed the stock up by 41.49%, with some analysts revising their revenue thesis to $73M-$96M.

Generated by AI

Vanda Pharmaceuticals

Social

Sep 30

Bullish· May 6

Bearish· May 6

Earnings· Aug 1

Announcements· Feb 24

Controversies· Jan 8

Technical Analysis· Feb 23

Regulars· Sep 29

Newcomers· Feb 24

Why is Vanda Pharmaceuticals stock surging today?

Yields bite, but 'smart money' still gorging on AI - Vanda (TLT:NASDAQ)

Vanda Pharmaceuticals at H.C. Wainwright conference: pipeline broadens

Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

Also Discussed

Vanda Pharmaceuticals Inc.

Company Information

Location

Why is Vanda Pharmaceuticals stock surging today?

Yields bite, but 'smart money' still gorging on AI - Vanda (TLT:NASDAQ)

Vanda Pharmaceuticals at H.C. Wainwright conference: pipeline broadens

Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

Also Discussed

Social

Sep 30

Bullish· May 6

Bearish· May 6

Earnings· Aug 1

Announcements· Feb 24

Controversies· Jan 8

Technical Analysis· Feb 23

Regulars· Sep 29

Newcomers· Feb 24